Natera

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). 

CEO
Stephen Leonard Chapman
CEOStephen Leonard Chapman
Employees
4,434
Employees4,434
Headquarters
Austin, Texas
HeadquartersAustin, Texas
Founded
2003
Founded2003
Employees
4,434
Employees4,434

NTRA Key Statistics

Market cap
31.85B
Market cap31.85B
Price-Earnings ratio
-103.29
Price-Earnings ratio-103.29
Dividend yield
Dividend yield
Average volume
1.03M
Average volume1.03M
High today
$235.01
High today$235.01
Low today
$229.17
Low today$229.17
Open price
$234.92
Open price$234.92
Volume
422.68K
Volume422.68K
52 Week high
$256.36
52 Week high$256.36
52 Week low
$125.38
52 Week low$125.38

Stock Snapshot

The current Natera(NTRA) stock price is $230.24, with a market capitalization of 31.85B. The stock trades at a price-to-earnings (P/E) ratio of -103.29.

On 2026-01-29, Natera(NTRA) stock traded between a low of $229.17 and a high of $235.01. Shares are currently priced at $230.24, which is +0.5% above the low and -2.0% below the high.

Natera(NTRA) shares are trading with a volume of 422.68K, against a daily average of 1.03M.

During the past year, Natera(NTRA) stock moved between $125.38 at its lowest and $256.36 at its peak.

During the past year, Natera(NTRA) stock moved between $125.38 at its lowest and $256.36 at its peak.

NTRA News

TipRanks 1d
Natera completes enrollment in ACES-EMB trial

Natera (NTRA) announced the completion of enrollment in ACES-EMB, the first randomized-controlled trial evaluating whether Natera’s Prospera Heart test can repl...

TipRanks 3d
Natera’s Prospera featured in interventional study advancing in lung transplant

Natera (NTRA) announced the publication of a new prospective clinical trial in Transplantation Direct. The study, which was conducted by The Ohio State Universi...

Simply Wall St 6d
How Investors May Respond To Natera MRD Breakthrough, AI Push And 2025 Revenue Outlook

Natera, Inc. recently reported a peer-reviewed validation in npj Precision Oncology for its Latitude tissue-free MRD assay in colorectal cancer, showing high se...

How Investors May Respond To Natera MRD Breakthrough, AI Push And 2025 Revenue Outlook

Analyst ratings

87%

of 23 ratings
Buy
87%
Hold
13%
Sell
0%

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.